Shots:
- Garda Therapeutics has entered into a definitive agreement to acquire Assertio, delisting it from Nasdaq
- As per the deal, Garda will acquire Assertio for $18/share in cash (~$125.1M) plus a non-tradeable CVR related to potential future milestones for Sprix, with the deal expected to close in Q2’26 & remaining shares acquired later via a second-step merger
- Concurrently, Assertio divested Indocin, Sympazan, Sprix, Cambia, Zipsor, & Otrexup to Cosette Pharmaceuticals for $35M upfront plus milestone-based earnouts, included in the total consideration of the Garda transaction
Ref: Businesswire | Image: Assertio |Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
